Evidence for the benefits of nonantipsychotic pharmacological augmentation in the treatment of depression

CNS Drugs

Volumn 27, Issue SUPPL.1, 2013, Pages

  Chang, Chia Ming ^a   Sato, Soichiro ^b   Han, Changsu ^c  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b Zikei Hospital   (Japan)

^c Korea University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BUSPIRONE; FOLIC ACID; LAMOTRIGINE; LIOTHYRONINE; LITHIUM; METHYLPHENIDATE; MODAFINIL; OMEGA 3 FATTY ACID; PINDOLOL; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; ANTIDEPRESSANT AGENT;

CLINICAL PRACTICE; DEPRESSION; DRUG EFFICACY; EVIDENCE BASED PRACTICE; FOOD AND DRUG ADMINISTRATION; HUMAN; MAJOR DEPRESSION; MEDLINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT RESISTANT DEPRESSION; DRUG COMBINATION; EVIDENCE BASED MEDICINE; META ANALYSIS (TOPIC); PSYCHOLOGICAL ASPECT;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; META-ANALYSIS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84886281128     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-012-0030-1     Document Type: Review

References (57)

1. Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of doubleblind, randomized clinical trials in MDD. Eur Neuropsychopharmacol. 2009;19(1):34-40.
2. Rush AJ, et al. STAR&z.ast;D: revising conventional wisdom. CNS Drugs. 2009;23(8):627-47.
3. Nierenberg AA, et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR&z.ast;D report. Psychol Med. 2010;40(1):41-50.
4. Paykel ES, et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med. 1995;25(6): 1171-80.
5. Thase ME. Evaluating antidepressant therapies: remission as the optimal outcome. J Clin Psychiatry. 2003;64(Suppl. 13): 18-25.
6. Philip NS, et al. Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era. Expert Opin Pharmacother. 2010;11(5):709-22.
7. Shelton RC, et al. Therapeutic options for treatment-resistant depression. CNS Drugs. 2010;24(2):131-61.
8. Zaratiegui R. STAR&z.ast;D study: searching strategies regarding lack of response to an SSRI. Vertex. 2009;20(84):119-28.
9. Connolly KR, Thase ME. If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs. 2011;71(1):43-64.
10. Chen J, Gao K, Kemp DE. Second-generation antipsychotics in major depressive disorder: update and clinical perspective. Curr Opin Psychiatry. 2011;24(1):10-7.
11. Dording CM, et al. The pharmacologic management of SSRIinduced side effects: a survey of psychiatrists. Ann Clin Psychiatry. 2002;14(3):143-7.
12. Mischoulon D, et al. Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians. Can J Psychiatry. 2000;45(5):476-81.
13. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry. 2000;157(4 Suppl.):1-45.
14. Lam RW, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord. 2009;117(Suppl. 1):S26-43.
15. Bauer M, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World J Biol Psychiatry. 2007;8(2):67-104.
16. Spijker J, Nolen WA. An algorithm for the pharmacological treatment of depression. Acta Psychiatr Scand. 2010;121(3): 180-9.
17. De Montigny C, et al. Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders. Br J Psychiatry. 1981;138:252-6.
18. Bauer M, Dopfmer S. Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol. 1999;19(5):427-34.
19. Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two metaanalyses of randomized, placebo-controlled trials. J Clin Psychiatry. 2007;68(6):935-40.
20. Heninger GR, Charney DS, Sternberg DE. Lithium carbonate augmentation of antidepressant treatment. An effective prescription for treatment-refractory depression. Arch Gen Psychiatry. 1983;40(12):1335-42.
21. Kantor D, et al. The benefit of lithium carbonate adjunct in refractory depression-fact or fiction? Can J Psychiatry. 1986;31(5): 416-8.
22. Zusky PM, et al. Adjunct low dose lithium carbonate in treatment-resistant depression: a placebo-controlled study. J Clin Psychopharmacol. 1988;8(2):120-4.
23. Schopf J, et al. Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition. Results of a placebo-controlled double-blind study. Pharmacopsychiatry. 1989;22(5):183-7.
24. Browne M, et al. Lithium as an adjunct in the treatment of major depression. Int Clin Psychopharmacol. 1990;5(2):103-10.
25. Joffe RT, et al. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry. 1993;50(5): 387-93.
26. Katona CL, et al. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry. 1995;166(1): 80-6.
27. Baumann P, et al. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapyresistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol. 1996;16(4): 307-14.
28. Bauer M, et al. Lithium's emerging role in the treatment of refractory major depressive episodes: augmentation of antidepressants. Neuropsychobiology. 2010;62(1):36-42.
29. Stein G, Bernadt M. Lithium augmentation therapy in tricyclicresistant depression. A controlled trial using lithium in low and normal doses. Br J Psychiatry. 1993;162:634-40.
30. Nierenberg AA, et al. Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants. J Clin Psychopharmacol. 2003;23(1):92-5.
31. Joffe RT, Singer W. A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants. Psychiatry Res. 1990;32(3):241-51.
32. Aronson R, et al. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry. 1996;53(9):842-8.
33. Altshuler LL, et al. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am J Psychiatry. 2001;158(10):1617-22.
34. Cooper-Kazaz R, Lerer B. Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors. Int J Neuropsychopharmacol. 2008;11(5):685-99.
35. Nierenberg AA, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR&z.ast;D report. Am J Psychiatry. 2006;163(9): 1519-30; quiz 1665.
36. DeBattista C, et al. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. J Clin Psychiatry. 2003;64(9):1057-64.
37. Fava M, Thase ME, DeBattista C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry. 2005;66(1):85-93.
38. Jacobsen FM. Possible augmentation of antidepressant response by buspirone. J Clin Psychiatry. 1991;52(5):217-20.
39. Trivedi MH, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354(12):1243-52.
40. Landen M, et al. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry. 1998;59(12): 664-8.
41. Appelberg BG, et al. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, doubleblind placebo wash-in study. J Clin Psychiatry. 2001;62(6): 448-52.
42. Onder E, Tural U. Faster response in depressive patients treated with fluoxetine alone than in combination with buspirone. J Affect Disord. 2003;76(1-3):223-7.
43. Ballesteros J, Callado LF. Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials. J Affect Disord. 2004;79(1-3):137-47.
44. Patkar AA, et al. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. J Clin Psychopharmacol. 2006;26(6):653-6.
45. Ravindran AV, et al. Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry. 2008;69(1):87-94.
46. Pae CU, et al. Methylphenidate extended release (OROS MPH) for the treatment of antidepressant-related sexual dysfunction in patients with treatment-resistant depression: results from a 4-week, double-blind, placebo-controlled trial. Clin Neuropharmacol. 2009;32(2):85-8.
47. Bloch MH, Hannestad J. Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis. Mol Psychiatry. 2011.
48. Lin PY, Su KP. A meta-analytic review of double-blind, placebocontrolled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry. 2007;68(7):1056-61.
49. Papakostas GI. Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. J Clin Psychiatry. 2009;70(Suppl. 6):16-25.
50. Sublette ME, et al. Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J Clin Psychiatry. 2011;72(12):1577-84.
51. Papakostas GI, et al. Serum folate, vitamin B12, and homocysteine in major depressive disorder. Part 1: predictors of clinical response in fluoxetine-resistant depression. J Clin Psychiatry. 2004;65(8):1090-5.
52. Alpert M, Silva RR, Pouget ER. Prediction of treatment response in geriatric depression from baseline folate level: interaction with an SSRI or a tricyclic antidepressant. J Clin Psychopharmacol. 2003;23(3):309-13.
53. Lazarou C, Kapsou M. The role of folic acid in prevention and treatment of depression: an overview of existing evidence and implications for practice. Complement Ther Clin Pract. 2010;16(3):161-6.
54. Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. J Affect Disord. 2000;60(2):121-30.
55. Green NS. Folic acid supplementation and prevention of birth defects. J Nutr. 2002;132(8 Suppl.):2356S-60S.
56. Fava M, Rush AJ. Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. Psychother Psychosom. 2006;75(3):139-53.
57. Thomas SP, Nandhra HS, Jayaraman A. Systematic review of lamotrigine augmentation of treatment resistant unipolar depression (TRD). J Mental Health. 2010;19(2):168-75.